# Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer

> **NCT02465502** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 59 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Regorafenib (Stivarga, BAY73-4506)

## Key facts

- **NCT ID:** NCT02465502
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-21
- **Primary completion:** 2017-05-02
- **Final completion:** 2017-12-11
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2018-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02465502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02465502, "Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02465502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*